{"code":0,"message":"","data":{"typeDesc":"新闻快讯","releaseTime":"2026-11-07T14:54:15","createPsn":"陈小泉","firstColumnCode":"JSKX","collectFlag":0,"source":"经理人融媒体中心","title":"盐酸阿罗洛尔原料药获批，华纳药厂原料制剂一体化布局推进","type":"XW","likesFlag":0,"collectAmount":0,"content":"<p style=\"text-indent: 2em; text-align: left;\">近日，华纳药厂（688799.SH）全资子公司湖南华纳大药厂手性药物有限公司，收到国家药监局下发的盐酸阿罗洛尔化学原料药上市申请批准通知书。该原料药与制剂同步审评审批结果为“A”，符合国内药品审评相关技术标准，可用于国内制剂生产。</p><p style=\"text-indent: 2em; text-align: left;\">盐酸阿罗洛尔是盐酸阿罗洛尔片的原料药，对应的片剂适用于轻至中度原发性高血压、心绞痛、心动过速性心律失常以及原发性震颤。</p><p style=\"text-indent: 2em; text-align: left;\">据CDE公开信息，当前共有7家企业完成该原料药登记，其中6家登记状态为A，1家登记状态为I。</p><p style=\"text-indent: 2em; text-align: left;\">盐酸阿罗洛尔原料药获批，将扩充公司产品矩阵，持续巩固原料制剂一体化的产业基础，提升企业核心竞争能力。</p>","downloadAmount":0,"filePageAmount":0,"releaseDateStr":"2026-11-07 14:54:15","fileUrl":"","readAmount":0,"columnCode":"","id":22537,"keyword":"","likesAmount":0,"statusDesc":"已上架","createPsnId":21,"firstColumnName":"即时快讯","updateTime":"2026-11-07 14:54:28","coverImgUrl":"","isExistFile":0,"createTime":"2026-11-07 14:54:28","authorName":"","isTop":0,"simpleContent":"","contentLength":0,"status":1,"columnName":null}}